Walgreens shareholders approve Sycamore Partners acquisition.

Walgreens Boots Alliance shareholders overwhelmingly approved the acquisition of the company by entities affiliated with Sycamore Partners Management, with approximately 96% of votes cast in favor of the merger agreement proposal. The transaction is expected to close in the third or fourth quarter of 2025.

Walgreens Boots Alliance (WBA) shareholders have overwhelmingly approved the acquisition of the company by entities affiliated with Sycamore Partners Management, with approximately 96% of votes cast in favor of the merger agreement proposal [1]. The transaction, which was initially announced in March 2025, is expected to close in the third or fourth quarter of 2025, subject to customary closing conditions, including the receipt of required regulatory approvals [1].

The acquisition, valued at around $10 billion, was approved by 96% of all shareholders and 95% of unaffiliated shareholders at the Special Meeting of Shareholders [1]. The merger agreement provides that WBA shareholders will receive $11.45 per share in cash at closing, with an additional potential cash payment of up to $3.00 per share from the future monetization of WBA's debt and equity interests in VillageMD [1]. VillageMD includes the Village Medical, Summit Health, and CityMD businesses.

Tim Wentworth, Chief Executive Officer of Walgreens Boots Alliance, expressed gratitude for the shareholders' support and optimism about the partnership with Sycamore. "With Sycamore’s partnership, we will be better positioned to accelerate our turnaround strategy, further enhance the customer, patient and team member experience and become the first choice for pharmacy, retail and health services," Wentworth stated [1].

The transaction is expected to have a significant impact on WBA's future business, results of operations, and financial condition. However, the company has outlined several risks and uncertainties associated with the transaction, including the possibility of not obtaining the necessary regulatory approvals, the risk of significant costs or expenses resulting from the transaction, and the potential disruption of current business operations [1].

Walgreens Boots Alliance, a global healthcare and retail leader, serves millions of customers and patients daily. The company employs approximately 312,000 people and operates in eight countries, with consumer brands including Walgreens, Boots, Duane Reade, No7 Beauty Company, and Benavides [1].

References:
[1] https://www.walgreensbootsalliance.com/news-media/press-releases/2025/wba-shareholders-approve-sycamore-transaction
[2] https://drugstorenews.com/walgreens-boots-alliance-shareholders-approve-pending-sycamore-partners-acquisition